Celltrion Is To Invest $33.6bn As It Lays Out Long-Term Ambitions

 
• By Jung Won Shin
  
Generate a summary of this article
Listen to this article
Beta

Celltrion unveils massive long-term investment plan to secure leadership in the global biopharma market, set up international sales distribution networks and support new bioventures and job creation, in the meantime contributing to Korea’s larger ambitions to develop as a worldwide drug industry hub.

Celltrion_Magnified
Celltrion Unveils Huge Investment Plan For Global Ambitions • Source: Shutterstock

Celltrion Inc., which has recently announced plans to establish its own global direct sales and distribution networks to seek further growth and improve margins, aims to invest a massive KRW40tn ($33.6bn) over the next 10 years in both biologics and chemical drugs, and in worldwide healthcare and U-healthcare (ubiquitous healthcare) platform businesses under a new long-term road map.

“Celltrion Group feels responsible as a leading South Korean biopharma firm and will focus on businesses that can beef up...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.